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Abstract
Premature ejaculation (PE; early ejaculation or rapid ejaculation) is a common sexual
problem affecting about 20-30% of men in the sexually active age group. PE can
be of four types: Primary, secondary, natural variable, and subjective PE. Various
non-pharmacological and pharmacological treatment options are available to treat PE
including Dapoxetine, which is specifically developed for the treatment of PE. In this
review, we discuss the pathophysiology and management aspects of PE.
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1. Introduction
Premature ejaculation (PE) is a common sexual
problem encountered by men in day-to-day
clinical practice. It affects about 20-30% of men
in the sexually active age group leading to
psychological stress and loss of self-esteem,
resulting in significant adverse effects on the
quality of life, of both the patient and the partner.
PE is a commonly used term, but it is more
appropriately called early ejaculation or rapid
ejaculation.
1.1. Definition
Although PE was reported in the medical
literature years back in 1887, its first acceptable
clinical definitionwas proposed in 1970 byMasters
and Johnson as “the inability of a man to delay
ejaculation long enough for his partner to reach
organism on 50% of intercourse attempts” (1).
PE is defined by The American Urology
Association as “ejaculation occurring sooner than
desired causing distress to one or both partners”
(2).
The International Society for Sexual Medicine
(ISSM) defines PE as:
“A male sexual dysfunction characterized
by ejaculation which always or nearly always
occurs prior to or within about one minute of
vaginal penetration (lifelong PE), or, a clinically
significant and bothersome reduction in latency
time, often to about 3 minutes or less (acquired
PE), and; inability to delay ejaculation on all or
nearly all vaginal penetrations; and negative
personal consequences, such as distress, bother,
frustration, and/or the avoidance of sexual
intimacy” (3).
2. Physiology of ejaculation
Ejaculation is the process by which sperms
moves from epididymis via vas deferens to
urethra and finally expelled out through the
urethral meatus by the contraction of smooth
muscles. A normal antegrade ejaculation consists
of emission, expulsion (ejection), and orgasm (4, 5)
(Figure 1).
Emission is the process of ejection of
spermatozoa along with the products of accessory
sexual gland secretion into the posterior urethra
by smoothmuscle contraction. The organ involved
in emission phase includes epididymis, vas
deferens, seminal vesicles, prostate gland,
prostatic urethra, and bladder neck. These
structures are supplied by both sympathetic
and parasympathetic nerves derived from
pelvic plexus. The closure of bladder neck
during emission phase prevents retrograde
ejaculation. Emission and closure of bladder
neck are mediated by thoracolumbar sympathetic
events which are mainly alpha adrenergic.
Expulsion is the process of ejection of sperms
from the urethra through the urethral meatus/glans
meatus. It is a spinal cord reflex occurring at the
“point of no return” by the contraction of the
smooth muscle of bladder neck, pelvic floor,
bulbospongiosus, and ischiocavernosus in
a stereotypical rhythmic pattern. The organ
involved in expulsion includes bladder neck and
urethra, and pelvic floor muscles. The smooth
muscles of bladder neck and proximal urethra
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receive both sympathetic and parasympathetic
supply. The external urethral sphincter and pelvic
floor muscles receive somatic nerve supply.
The muscles involved in expulsion phase are
innervated by pudendal nerve and the motor
neurons located in the nucleus of Onuf (ON).
Normal pelvic floor function is important for
normal sexual function. The superficial layer of
male pelvic floor consists of bulbospongiosus,
ischiocavernous, superficial transverse perineal
muscle and external anal sphincter. These
muscles are important in the control of urination,
ejaculation, penile rigidity, and hardness during
erection (6).
There are two central pattern generator for
ejaculation, one for emission phase which is
located in the upper lumbar cord (L2/L4) and the
other for expulsion phase located in upper sacral
cord (probably in S1/S2). Ejaculation is a reflex
activity which is influenced by cerebral control.
Spinal ejaculation generator act as a modulator of
the emission and expulsion phase of ejaculation
by coordinating genital sensory inputs, motor
outputs, and descending supra spinal modulation
from brain region (7).
A “spinal ejaculatory generator” integrates
peripheral and central stimuli and its function
is important in the process of ejaculation.
The spinal ejaculation generator is under the
influence of supraspinal area including nuclease
paragigantocellularis, paraventricular nucleus
of hypothalamus, and the medial preoptic
area. The projection from the paraventricular
hypothalamic nucleus terminates in the lumbar
preganglionic motor neurons, nucleus of
ON, sacral parasympathetic motor neurons,
and neurons in the area of lamina X, where
ejaculation generators are supposed to be
located. Serotonergic projections from the
nucleus paragigantocellularis (nPGi) in the brain
stem exert tonic inhibition of ejaculation via
motor nucleus in the lumbosacral spinal cord,
influencing the spinal ejaculation generator in the
spinal control center located in the lumbosacral
spinal cord.
Ejaculation involves various cerebral and
spinal areas which are interconnected. The
various neurotransmitters involved in ejaculation
include serotonin (5HT), dopamine, oxytocin,
gama-aminobutyric acid (GABA), adrenaline,
acetylcholine, and NO. Among these, 5HT
has a primary role in ejaculation and is mainly
inhibitory. 5HT1A, 5HT1B, 5HT2A, and 5HT7
receptor subtypes are mainly involved in the
control of ejaculation. The neurotransmitter
serotonin (5 Hydroxytryptamine-5HT) in the brain
descending pathway inhibits ejaculation reflex.
Activation of postsynaptic 5HT receptors, by 5HT
in the synaptic cleft increases ejaculatory latency.
Overstimulation of postsynaptic 5HT receptor
is checked by three inhibitory mechanisms: (1)
Activation of presynaptic 5HT1A receptors, which
reduces the firing rate of the neuron leading
to inhibition in the release of 5HT into the
synaptic cleft. (2) Activation of 5HT1B receptors
that reduce the release of 5HT in the synaptic
cleft. (3) 5HT reuptake transports (5HTT), located
at the presynaptic terminals and serotonergic cell
bodies remove 5HT from the synaptic cleft into the
presynaptic neurons (8) (Figure 2).
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Studies have shown that during ejaculation,
the strongest activation occurs in the meso-
diencephalic region. The strongest activation
seen in structures like ventral tegmental area
(reward area), ventromedial posterior thalamic
nucleus, subparafasicular nucleus, intralaminar
nuclei, and lateral central tegmental field). Other
areas showing increased activation include
lateral putamen, parts of prefrontal, temporal,
parietal, and insular cortex and cerebellum.
The medial part of the amygdale region,
which constantly monitors the environmental
stimuli is deactivated during sexual activity
(9).
Figure 1. Physiology of ejaculation (see text for explanation). BNSTp: Posteromedial bed nucleus of stria terminalis; MEApd:
Posterodorsal medial amygdaloid nucleus; MPOA: Medial preoptic area; PAG: Periaqueductal grey; nPGi: Paragigantocellular
nucleus; PNpd: Posterodorsal preoptic nucleus; PVN: Paraventricular thalamic nucleus; SPFp: Parvicellular part of the
subparafascicular thalamus (4, 6, 8, 9).
3. Pathophysiology
Serotonin (5 Hydroxytryptamine-5HT) inhibits
ejaculation reflex leading to prolonged ejaculation
latency time. 5HT receptor agonists (5HT2𝑐 )
also delay ejaculation (10). However, the low
level of 5HT neurotransmission/hyposensitivity of
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postsynaptic 5HT receptors in brain stem/spinal
cord results in low inhibition, resulting in rapid
ejaculation. Genetic predisposition resulting in
impairment of serotonergic pathway can also
cause PE (Figure 2).
According to the Waldinger’s theory
of pathophysiology of PE, low levels of
5HT/hyposensitivity of 5HT2c receptor or hyper
sensitivity of 5HT1A receptor cause PE.
In males, the pelvic floor dysfunction is
associated with various sexual problems including
erectile dysfunction ED and sexual dysfunction
associated with ejaculation and orgasm.
Active perineal muscle control can
inhibit ejaculation reflex via relaxation of
bulbospongiosus and ischiocavernous muscles
(11).
To summarieze, 5HT is the major
neurotransmitter involved in the process of
ejaculation and inhibits ejaculation reflex. Thus, a
low level of 5HT or 5HT receptor hyposensitivity
leads to PE, and drugs that increase the level of
5HT are useful in the treatment of PE.
Figure 2. Mechanism of action of Dapoxetine in PE. (A) Synapse showing serotonin in normal individual. (B) Synapse showing
reduced serotonin in people with PE. (C) Synapse showing improved serotonin level in people with PE treated with dapoxetine.
5HT: 5 Hydroxytryptamine or Serotonin.
4. Causes of PE
While PE is a common sexual dysfunction
affecting all age groups, ED is more prominent in
older age group and more commonly associated
with other medical conditions like diabetes.
Primary PE can be triggered by psychological
impulses like conditioning, upbringing, or
traumatic sexual experience. Secondary PE
can be triggered by diabetes, hypertension,
hyperthyroidism, alcoholism, or use of recreational
drugs. Psychological issues like depression,
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stress, or anxiety about sexual performance
can also trigger PE. In addition, hyperthyroidism
is associated with PE and treating the same
results in improvement of PE. PE is common in
patients with substance abuse. Besides, lack of
sleep can lead to low serotonin, also resulting in
PE.
5. Clinical features
PE is a self-reported problem, which not only
affects the patient, but also the partner, and
it also depends on the patient’s expectation
and belief regarding sexual intercourse. Hence,
people who are able to perform sexual activities
for reasonably good duration of time may also
complai of PE due to unrealistic expectation
about sexual activity. Measurement of intravaginal
ejaculation latency time (IELT) is an attempt to
define PE in terms of time taken to ejaculate,
but it will not take into consideration the
consequent psychological difficulty and distress,
which are the main factors determining the
quality of life and compelling the patient to
seek medical attention. IELT is defined as
the time interval between vaginal penetration
and intravaginal ejaculation which is usually
measured using a stopwatch and showed a
positively skewed distribution with a median IELT
of 5.4 min (0.55-44.1m) which decreases with age
(12).
Sexual assessment monitor (SAM) is a
novel portable device which measures time
to erection and ejaculation. The device has
a control box, a vibrator, and a sensor. The
vibrator and sensor are attached to the penis.
The vibrator helps to provides a non-manual
stimulation whereas the sensor measures the
time to erection and ejaculation. SAM generates
ELT from electronically collected data. This
helps in the objective measurements of ELT,
resulting in more appropriate diagnosis of PE
(13).
In patients with PE, we have to consider the time
taken to ejaculate (ejaculate latency), the ability
to control ejaculation, and the psychological
(frustration) distress and its impact on the
quality of life. The partner’s attitude and the
intersexual relationship between the couple
should also be assessed. Patients with PE may
have a tendency to avoid sexual intercourse,
in order to escape from the psychological
distress.
The inability to delay or control orgasm is
considered to be an important factor as majority
of patients with PE reports poor/ very poor
ejaculatory control. But However, a number of
studies have demonstrated only moderate or no
correlation between IELT and reported ejaculatory
control (14). PE causes psychological distress,
anxiety, embarrassment and depression, erectile
dysfunction, reduced libido, poor interpersonal
relationship and, difficulty in relaxation and anxiety
about intercourse. It also causes low scoring in
self-esteem and relationship questionnaire, in
all measures of intimacy on psychological and
interpersonal relationship scale, greater distress
on PE profile scale, decreased self-esteem
and confidence during sexual encounters (15,
16).
Although the currently proposed definition
focusses only on vaginal penetration, it fails
to address other sexual activities like oral/anal
sex and masturbation. However, in these sexual
activities, sometimes partner’s orgasm may not
be an important factor, thereby reducing the
clinical significance and associated psychological
stress.
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5.1. Classification of PE
PE can be classified into four major types:
(1) Primary/life-long PE; (2) secondary/acquired
PE; (3) natural variable PE; and (4) subjective
PE/premature-like ejaculatory dysfunction.
A primary PE is a form of PE which begins
when a male becomes sexually active,
while a secondary PE begins later in sexual
life.
While a primary or Life-long PE is characterized
by an IELT of <1 min since first intercourse,
an acquired or secondary PE usually has an
IELT of < 3 min at any given time (17). On the
other hand, a variable PE is a normal variant
of sexual function. In premature-like ejaculatory
dysfunction, a person is preoccupied with early
ejaculation or lack of ejaculatory control, but the
IELT will be within normal limit (18) (Table I).
Moreover, PE can be divided into global or
situational, depending the circumstances, and
further divisions can be made depending on the
type of sexual activity. Another classification of PE
depending upon the etiology is “psychogenic PE”
and “biogenic PE”.
Table I. Types of premature ejaculation and its features
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Erectile dysfunction can coexists with PE, asman
with ED ejaculate early, before the loss of erection;
and identification of this situation is important in the
management (19, 20). The loss of erection before
ejaculation helps to differentiate ED from PE.
5.2. Approach to PE
PE is a clinical diagnosis. Female orgasm can
be affected by various factors, and lack of proper
history from the female partner may lead to
misdiagnosis of female organismic disorder as
male partner’s PE, again emphasizing the concept
of considering sexual partners as a single unit
for evaluation and treatment of various sexual
problems. The definitions of PE is based on the
assumption that female partner is not having any
sexual dysfunction like vaginismus or delayed
orgasm.
Patients presenting with a history of rapid
ejaculation should be asked about the duration
of symptoms (primary vs. acquired), about any
difficulty in erection, whether he loses erection
before ejaculation (PE secondary to ED), whether
having rapid ejaculation only during some situation
or always/most of the time? (Situational vs.
global).
The patient and his partner’s perception can
be assessed by asking “what is the approximate
time between penetration and ejaculation? Is that
annoying you or your partner? Is it affecting your
relationship? Do you or your partner avoid sexual
contact because of this? The answer will give an
idea about the severity of the problem and its
impact on life.
In addition, questions like “Do you ejaculate
even before penetration? Are you able to delay
ejaculation?” will give idea about the perceived
degree of control over ejaculation. Also, a
stopwatch measurement of IELT will help to
quantify the problem (Figure 3).
Detailed history of a previous sexual function
and sexual relationship will give a clue about the
probable causes in case of secondary or acquired
PE.
Moreover, detailed history of other medical
problems (like diabetes, hypertension, and
hyperthyroidism) and history of intake of
medications, trauma or injection will help to
identify secondary causes, if there is any.
History of any psychological/psychiatric
problems leading to PE and psychological
/psychiatric problems secondary to PE must
also be assessed and addressed.
Screening questionnaires like premature
ejaculation diagnostic tool (PEDT) or arabic index
of premature ejaculation (AIPE) along with relevant
clinical examination will help diagnose PE in
patients with sexual dysfunction (21). Additionally,
the index of premature ejaculation (IPE) and
male sexual health questionnaire-ejaculatory
dysfunction (MSHQ-EjD) can help characterize PE
and assess treatment responses.
Several studies have shown that about 80-90%
of men with lifelong PE ejaculate within 60 sec and
the remaining within 2 min.
The perception about normal ejaculatory latency
varies according to country, religious beliefs, and
expectation of the patient and his partner, which
can also influence the diagnosis of PE.
The clinical examination in patients with PE
includes abdominal and genital examination along
with neurological examination and examination
of lower limb. However, most of the time, these
are within normal limits. The clinical examination
will also help to reassure the patients that they
are anatomically normal. A rectal examination
is usually done if PE is associated with painful
ejaculation.
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6. Treatment
The treatment of PE includes non-
pharmacological and pharmacological treatment
(Table II).
6.1. Non-pharmacological treatment
Psychotherapy and various behavioral therapies
are used in the treatment of PE. Psychological
therapy requires strong compliance from the
partner and is time-consuming, expensive, and less
effective than pharmacotherapy and its efficiency
decreases with time (22). However, it is the first-line
therapy in patient with subjective PE or PE with
underlying psychological problem. Psychotherapy
is also effective in managing the psychological
distress associated with sexual dysfunction.
Psychosexual counseling is important to address
psychological distress due to PE. Methods like
meditation/relaxation, hypnotherapy and neuro-
biofeedback help improve ejaculatory control.
Various behavioral therapies are also useful in
patients with PE which includes masturbation
before coitus (precoital masturbation) “stop-
start” and “squeeze” techniques, use of multiple
condoms, and pelvic floor exercise (23).
The ‘Stop-start’ method, proposed by Semans
in 1956 and “squeeze” techniques, by Masters
and Johnson in 1970 are the two commonly used
techniques for PE.
Table II. Treatment options for premature ejaculation
Non pharmacological treatment Pharmacological treatment
Psychosexual counseling Dapoxetine
Psychotherapy Topical anesthetic cream
Meditation/relaxation, hypnotherapy Tramadol
Precoital masturbation TCA*: Clomipramine
“Stop-start” and SSRIs**: Paroxetine, Fluoxetine, Serta line
“Squeeze” techniques, PDE-5 inhibitors***
Use of multiple condoms Emerging treatment
Pelvic floor exercise Circumcision
Extended foreplay Dorsal penile nerve cryoablation
Cognitive distraction Neuromodulation
Alternate sex positions Hyaluronic acid gel glans augmentation
Interval sex Botulism toxin injection
Increasing frequency of sex
Acupuncture
* Tricyclic antidepressants, ** Selective serotonin reuptake inhibitors, *** Phosphodiesterase (PDE 5) inhibitors
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Figure 3. Premature ejaculation management algorithm. S/o: Suggestive of; PE: Premature ejaculation; ED: Erectile dysfunction;
PEDT: Premature ejaculation diagnostic tool; AIPE: Arabic index premature ejaculation; IELT: Intravaginal ejaculatory latency time;
EC: Ejaculatory control.
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6.1.1. “Squeeze” technique
Identifying the “points of no return” (i.e., the point
where one feels that ejaculation is imminent and
inevitable) during intercourse is an important step
in “stop-start” and “squeeze” techniques. In the
squeeze technique, the patient holds the penis
with thumb and forefinger at the “points of no
return” in such a way that the thumb comes
over the frenulum and the two forefingers on
the opposite side where glans meet the shaft
of the penis and squeeze for few seconds. This
sustained pressure applied to glans penis results
in the contraction of bulbospongiousus muscle
via bulbospongiosus reflex leading to diminished
ejaculatory urgency, loss of desire to ejaculate
and reduced rigidity of penis, thereby helping to
prolong sexual activity. Stopping the motion of
intercourse and performing sustained contraction
of the pelvic floor muscles can also result in
diminished ejaculatory urgency which is described
as “internal squeeze” without manual pressure
(24). In men with pelvic floor muscle dysfunction,
the pelvic floor therapy significantly increase IELT,
making it a safe and effective treatment option in
PE (25).
6.1.2. “Stop-start” technique
In this technique, the partner stimulates the
penis until the patient feels the urge to ejaculate.
At this point, the patient should stop stimulation
and wait for the sensation to pass. Then, they have
to stimulate again till the “points of no return” and
stop it, thereby helping to prolong sexual activity.
Subsequently, the “Stop-start” technique can be
practiced during intercourse.
Pelvic floor exercises/Kegel exercises help
strengthen pelvic floor muscles. It also helps
to control ejaculation. Wearing condom during
intercourse reduces the sensitivity and helps delay
ejaculation in patients with PE. Other behavioral
techniques include extended foreplay, cognitive
distraction, alternate sex positions, interval sex,
and increasing the frequency of sex. Acupuncture
is also proposed to be effective in improving IELT.
6.2. Pharmacological treatment
6.2.1. Topical anesthetic cream
Topical anesthetic cream containing lidocaine
and pilocarpine applied to penis about 20
min before sexual intercourse increases IELT
from 1.49 to 8.45 min (26). Topical eutectic-
like mixture for PE, which is a metered dose
aerosol containing lidocaine and pilocarpine,
also improves IELT 2.4 times than the
baseline and is easy to use (27) (Table
III).
However, it can cause numbness of genitalia of
males, and sometimes because of contamination
of cream in vagina, the partner can also have
numbness during intercourse (28). Use of condom
can prevent transvaginal absorption. Use of topical
anesthetic preparations can also be associated
with loss of pleasure, orgasm, and erection.
https://doi.org/10.18502/ijrm.v19i1.8176 Page 15
International Journal of Reproductive BioMedicine Raveendran et al.
Table III. Drugs used to treat Premature Ejaculation
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Table III. Continued
Alpha-1 adrenoceptor antagonist (alpha-1 blocker)
Tamsulosin 0.4 mg 6-9 hr Postural hypotension,dizziness






PE: Premature ejaculation, ED-Erectile dysfunction, IELT: Intra-vaginal ejaculation latency time, TCAs: Tricyclic antidepressants,
SSRIs: Selective serotonin reuptake inhibitors
6.2.2. Tramadol
Tramadol is commonly used as an analgesic.
It acts as a μ-opioid agonist and an inhibitor of
reuptake of 5 hydroxytryptamine (5 HT) and nor-
adrenaline (NA). It is useful in the management
of PE, through a multimodal mechanism that
involves inhibition of reuptake of 5 HT and NA,
blockade of nociceptive effects, and inhibition of
spinal somatosensory-evoked potentials. Because
of the short half-life (1.7 hr) and rapid absorption,
it can be used as “on demand” tablet (56 mg 2
hr prior to the intercourse) for the treatment of
PE (29). It significantly increases IELT, heightens
sexual satisfaction, and improves control over
ejaculation.
6.2.3. Serotonergic antidepressants:
Tricyclic antidepressants (TCA) and
selective serotonin reuptake inhibitors
(SSRIs)
6.2.3.1. Tricyclic antidepressants (TCA)
TCA inhibit norepinephrine transporter (NET)
and serotonin transporter (SERT) and reduce the
uptake of noradrenaline and 5-HT by adrenergic
and 5-HT neurons. Serotonin inhibit ejaculation,
while TCA and SSRIs potentiate its effect, and
hence are useful in the management of PE. Among
TCAs, clomipramine is used as an “off label drug”
to treat PE. Other TCAs are not commonly used to
treat PE because of its potential side effect profile
(30).
6.2.3.2. Selective serotonin reuptake
inhibitors (SSRIs)
SSRIs like paroxetine, fluoxetine, sertraline
increases IELT by reducing the uptake of serotonin
via blockade of 5-HT transporters and used as an
“off label drug” to treat PE (31).
6.2.4. Dapoxetine
Dapoxetine is a potent SSRI and the first
molecule specifically developed for the treatment
of PE. It binds to 5HT, nor-epinephrine (NE) and
dopamine (DA) reuptake transporters and inhibits
their uptake in the order of potencyNE<5HT>>DA,
thereby increasing 5HT level in the synaptic cleft
(Figure 2).
The chemical structure is Dapoxetine ((+)-(s)-
N, N-dimethyl-A- {2-(1-naphthalenyloxy) ethyl} -
benzene methenamine) hydrochloride. Dapoxetine
is absorbed rapidly (1-3 hr), the maximum plasma
https://doi.org/10.18502/ijrm.v19i1.8176 Page 17
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concentration is reached after 1-2 hr with a
half-life of 60-80 min, and is eliminated almost
completely within 24 hr, and therefore can be
used as “on demand drug” for the treatment of PE.
Dapoxetine should be swallowed with one glass
of water to avoid bitter taste. It is metabolized
by multiple enzymes including cytochrome
P450 isoforms and flavin monoxygenase-1
and excreted in urine, after metabolism (32).
When co-administered with potent CYP2D6
or CYP3A4 inhibitors, the level of Dapoxetine
increases.
The recommended initial dose of Dapoxetine is
30 mg, taken as needed 1-3 hr before sexual
activity once in every 24 hr and may be
increased to a maximum dose of 60 mg daily
based o tolerability if 30 mg is insufficient to
produce desired therapeutic effects. However,
if Dapoxetine is taken ‘on demand’1-3 hr before
sexual activity, it should not be taken again
before 24 hr of intake. With 30 mg Dapoxetine
the mean IELT increase from 0.9-1.1 min to
2.8-3.9 min and with 60 mg to 3.3-4.2 min
compared to placebo (1.8-2.4 min) (33-35). The
common side effects of Dapoxetine include
nausea, diarrhea, headache, dizziness, insomnia,
somnolence, fatigue, and nasopharyngitis. It
rarely causes erectile dysfunction. Dapoxetine
is found to be safe in therapeutic dosage. It
does not cause prolongation of QT interval
or increase the risk of significant arrhythmia.
Dapoxetine should not be taken with alcohol
Since Dapoxetine can produce orthostatic
hypotension and syncope, patients are advised
to avoid rapid position change within 3 hr of
intake of the tablet. An orthostatic test can be
done before starting Dapoxetine to assess the
risk.
Also, Dapoxetine withdrawal does not produce
significant symptoms in contrast to other SSRI
withdrawal that produce symptoms such as
dizziness, headache, nausea, vomiting, diarrhea,
and occasionally agitation, impaired concentration,
depersonalization, and irritability.
It is advised to attempt gradual withdrawal of
drugs in selected patients, especially in those with
acquired PE after six-eight weeks of treatment.
6.2.5. Phosphodiesterase-5 (PDE5)
inhibitors
PDE-5 inhibitors do not increase IELT; however,
in patients with PE, it increases the perception
of ejaculatory control, ejaculatory confidence, and
overall sexual satisfaction (36).
In patients with concomitant PE and ED, PE can
be secondary to ED. In such cases, ED should
be treated first and PE usually improves with
improvement in ED.
PDE-5 inhibitors reduce the refractory time to
achieve second erection after ejaculation. Some
studies have shown that a combination of PDE-
5 inhibitor along with SSRIs increases IELT and
sexual satisfaction compared with SSRIs alone,
however, it is associated with a higher side effects
profile, like headaches and flushing (37). The
proposed mechanisms for the benefits of PDE-
5i in the treatment of PE includes (a) a central
effect resulting in increased NO and reduced
sympathetic tone, (b) relaxation of the smooth
muscles of vas deferens and seminal vesicles;
and (c) reduction in anxiety associated with
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sexual performance. However, till now, there is
no clear evidence on a combination of PDE-5
inhibitors and SSRIs in patients with PE without
ED.
6.2.6. Alpha-1 adrenoceptor antagonist
(alpha-1 blocker)
Alpha-1 blockers are useful for the treatment
of patients with concomitant PE and lower
urinary tract symptoms (LUTS). Alpha blocker,
tamsulosin, which is commonly used to treat
benign prostatic hyperplasia showed a significant
inhibit on the emission phase of ejaculation due
to decreased contractility of the seminal vesicle or
the vas deferens. This increased the ejaculatory
threshold, resulting in the beneficial effect in
PE. Tamsulosin also reduces ejaculatory volume.
Silodosin, a new alpha-1 blocker with powerful
affinity toward the alpha-1A adrenoceptor
prolongs IELT with three-fold longer than the
baseline (38).
6.3. Emerging treatment
Surgical treatment option like circumcision
is under investigation. Dorsal penile
nerve cryoablation, neuromodulation, and
hyaluronic acid gel glans augmentation and
botulinum toxin injection into ejaculatory
muscles are currently under clinical trial
(39, 40) (Figure 4). Other potential future
therapeutic options for PE that are under
research include Dopamine Receptor
Antagonists (selective D3 blockers),
GABA-B partial agonists, Serotonin 1A
Receptor antagonists, oxytocin receptor
antagonists (Epelsiban), Neurokinin-1 receptor
antagonists, and Purinergic 2 receptor
antagonists.
Figure 4. Surgical procedures in the treatment of PE and its mechanism.
7. Prognosis
Various data show that the success rate
with behavioral and pharmacologic therapy is
very high (> 85%) in people with PE. However,
the relapse rate is also high and ranges from
20 to 50%. In patients with lifelong PE, IELT
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will return to pretreatment level within one-
three weeks after stopping the medications,
whereas in patients with acquired PE, treatment of
precipitating factors like ED, sexual performance
anxiety will result in sustained improvement
in IELT even after stopping medicines like
SSRIs.
8. Conclusion
PE is a common sexual problem, which
cause distress to the patient and his partner.
The pathophysiological mechanism is complex.
Diagnosis is mainly clinical. Behavioral techniques
and psychotherapy have been the main modes
of therapy for years. Topical anesthetic creams,
TCA and SSRIs tramadol, Alpha-1 adrenoceptor
antagonist and PDE-5 inhibitors were the main
treatment modalities for years. Development of
newer drugs like Dapoxetine have promising role
in the management of PE.
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